drugset / Trial / NCT00000529

Tamoxifen Study

NCT00000529

RandomizedPrevention

Summary

To assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. The National Cancer Institute initiated the prevention trial under its National Surgical Adjuvant Breast and Bowel Project (NSABP). The National Heart, Lung, and Blood Institute provided support to obtain blood pressure and lipid measurements, and lipoprotein and selected coagulation factor measurements in a subsample.

Timeline

Start
1992-05
Primary completion
Completion
1995-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 10 mg